Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 5/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.61 |
| ▸ | AKR1C1 | Q04828 | 4/20 | 0.55 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.49 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.46 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.46 |
| ▸ | MLYCD | O95822 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL988946 | 0.92 | AKR1C1 (0.62) | APPCYP2C19CYP2C9CYP3A4AKR1C1 | |
| SCHEMBL1421838 | 0.92 | AKR1C1 (0.68) | APPCYP2C19CYP2C9CYP3A4AKR1C1 | |
| SCHEMBL17761264 | 0.91 | APP (0.54) | APPCYP2C19CYP2C9CYP3A4AKR1C1 | |
| SCHEMBL1807150 | 0.90 | AKR1C1 (0.66) | APPCYP2C19CYP2C9CYP3A4AKR1C1 | |
| Hydrochloric Acid SCHEMBL28577324 | 0.90 | AKR1C1 (0.66) | APPCYP2C19CYP2C9CYP3A4AKR1C1 | |
| SCHEMBL378896 | 0.87 | APP (0.50) | APPCYP2C19CYP2C9CYP3A4AKR1C1 | |
| SCHEMBL166581 | 0.87 | APP (0.50) | APPCYP2C19CYP2C9CYP3A4AKR1C1 | |
| SCHEMBL5768239 | 0.87 | CYP2C9 (0.50) | APPCYP2C19CYP2C9CYP3A4AKR1C1 | |
| SCHEMBL3219496 | 0.86 | APP (0.50) | APPCYP2C19CYP2C9CYP3A4AKR1C1 | |
| Hydrochloric Acid SCHEMBL5916170 | 0.85 | APP (0.49) | APPCYP2C19CYP2C9CYP3A4AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111162313-A | Polymer electrolyte and lithium ion battery | 珠海冠宇电池有限公司 | 2020-05-15 | — | — | CN | claimed |
| US-20080039482-A1 | SULFONAMIDO-MACROCYCLES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-02-14 | — | — | US | claimed |
| WO-2007147574-A1 | SULFONAMIDO-MACROCYCLES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-27 | — | — | WO | claimed |
| EP-1870416-A1 | Sulphonamido-macrocycles as tie2 inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-12-26 | — | — | EP | claimed |
| EP-4743174-A1 | MODULATORS OF CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | Aconcagua Bio, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20250276972-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | GRITSCIENCE BIOPHARMACEUTICALS CO LTD (CN) | 2025-09-04 | — | — | US | disclosed |
| US-20250042916-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ACONCAGUA BIO, INC. | 2025-02-06 | — | — | US | disclosed |
| WO-2025015268-A1 | MODULATORS OF CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | ACONCAGUA BIO, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| WO-2024086804-A1 | INDOLIZINE DERIVATIVES FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20240025917-A1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-01-25 | — | — | US | disclosed |
| CN-116917293-A | Plasma kallikrein inhibitors | 默沙东有限责任公司 | 2023-10-20 | — | — | CN | disclosed |
| EP-4247372-A1 | PLASMA KALLIKREIN INHIBITORS | Merck Sharp & Dohme LLC (US) | 2023-09-27 | — | — | EP | disclosed |
| US-7179802-B2 | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2007-02-20 | — | — | US | disclosed |
| CN-1659151-A | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO INC (US) | 2005-08-24 | — | — | CN | disclosed |
| EP-1532122-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | Merck & Co., Inc. (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20040106664-A1 | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK SHARP & DOHME LLC | 2004-06-03 | — | — | US | disclosed |
| US-6730690-B2 | DELAYING THE ONSET OR REDUCING THE RISK OF DEVELOPING ATHEROSCLEROSIS IN A HUMAN PATIENT COMPRISING ADMINISTERING TO SAID PATIENT AN EFFECTIVE AMOUNT OF A COMPOUND OF INVENTION AND AN HMG-COA REDUCTASE INHIBITOR | MERCK & CO., INC. | 2004-05-04 | — | — | US | disclosed |
| US-20040048912-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | MERCK SHARP & DOHME LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003104208-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | MERCK & CO., INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| WO-2003104207-A2 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | MERCK & CO., INC. (US) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048912-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | HSD11B1, HSD17B1, HSD11B2 | APP 3830/4885CYP2C19 266/4885CYP2C9 298/4885 |
| US-20040106664-A1 | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | HSD11B1, HSD11B2, HSD17B1 | APP 4128/4885CYP2C19 152/4885CYP2C9 207/4885 |
| US-20080039482-A1 | SULFONAMIDO-MACROCYCLES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | TIE1, KDR, TEK | APP 2347/4885CYP2C19 1997/4885CYP2C9 1627/4885 |
| US-20240025917-A1 | PLASMA KALLIKREIN INHIBITORS | KLKB1, SERPINE1, KLK5 | APP 1202/4885CYP2C19 1027/4885CYP2C9 1606/4885 |
| US-20250042916-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | IAPP, GIPR, GPR119 | APP 69/4885CYP2C19 4572/4885CYP2C9 4648/4885 |
| US-20250276972-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | PACSIN2, CSNK1A1, CSNK1G3 | APP 3107/4885CYP2C19 1990/4885CYP2C9 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.